Spinal Cord Injury

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 53 58 37 17
Spinal Cord Injuries 42


Orphanet epidemiological data:

spinal cord injury
Prevalence: 1-5/10000 (Europe);


Orphanet: 58  
Rare neurological diseases

External Ids:

ICD10 via Orphanet 33 T09.3
UMLS via Orphanet 72 C0037929
Orphanet 58 ORPHA90058

Summaries for Spinal Cord Injury

MedlinePlus : 42 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures (breaks) or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to acute cystitis and decubitus ulcer. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Hydromorphone and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are behavior/neurological and cellular

NINDS : 53 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 74 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 986)
# Related Disease Score Top Affiliating Genes
1 acute cystitis 32.8 TNF IL6 CXCL8
2 decubitus ulcer 32.0 TNF MMP9 IL6
3 constipation 31.4 NOS2 GDNF BDNF AQP4
4 brain injury 31.2 IL6 GFAP CASP3 BDNF AQP4
5 traumatic brain injury 31.0 MMP9 IL6 GFAP CASP3 BDNF AQP4
6 pyelonephritis 31.0 TNF IL6 CXCL8
7 bone resorption disease 30.9 TNF LEP IL6
8 osteomyelitis 30.8 TNF IL6 CXCL8
9 cerebral palsy 30.8 TNF IL6 CXCL8 BDNF
10 severe acute respiratory syndrome 30.7 TNF IL6 CXCL8
11 exanthem 30.6 TNF IL6 CXCL8
12 spinal cord disease 30.6 TNF IL6 GFAP GDNF AQP4
13 pulmonary edema 30.5 TNF NOS2 CXCL8
14 non-alcoholic steatohepatitis 30.5 TNF IL6
15 major depressive disorder 30.4 TNF LEP IL6 GDNF BDNF
16 sleep disorder 30.4 TNF LEP IL6 BDNF
17 nervous system disease 30.4 TNF NOS2 MMP9 IL6 BDNF
18 prostatitis 30.4 TNF IL6 CXCL8 CASP3
19 aortic disease 30.4 NOS2 MMP9 IL6
20 cerebral artery occlusion 30.4 TNF GDNF BDNF AQP4
21 arteriovenous malformation 30.4 TNF MMP9 IL6
22 bronchitis 30.3 TNF MMP9 IL6 CXCL8
23 urethritis 30.3 TNF IL6 CXCL8
24 disease of mental health 30.3 TNF LEP IL6 BDNF
25 complex regional pain syndrome 30.3 TNF IL6 GFAP CXCL8
26 colitis 30.2 TNF NOS2 IL6 CXCL8
27 sleep apnea 30.2 TNF LEP IL6 CXCL8 BDNF
28 neuroma 30.2 IL6 GFAP GDNF AQP4
29 neurofibromatosis, type ii 30.2 TNF IL6 CXCL8
30 brain edema 30.2 NOS2 MMP9 IL6 GFAP AQP4
31 fasciitis 30.2 TNF IL6 GFAP CXCL8
32 leptin deficiency or dysfunction 30.2 TNF LEP IL6 BDNF
33 myelitis 30.2 TNF MMP9 IL6 CXCL8 AQP4
34 ischemia 30.1 NOS2 GJA1 GFAP CASP3 BDNF
35 proteasome-associated autoinflammatory syndrome 1 30.1 TNF NOS2 MMP9 IL6 CXCL8
36 toxic shock syndrome 30.1 TNF NOS2 IL6 CXCL8
37 cystitis 30.1 TNF NOS2 IL6 GDNF CXCL8 BDNF
38 primary progressive multiple sclerosis 30.1 TNF MMP9 BDNF
39 peritonitis 30.1 TNF NOS2 IL6 CXCL8
40 limb ischemia 30.1 TNF MMP9 IL6
41 transverse myelitis 30.1 TNF MMP9 IL6 CXCL8 AQP4
42 meningoencephalitis 30.1 TNF IL6 GDNF BDNF
43 osteoarthritis 30.1 TNF MMP9 IL6 CXCL8
44 pulmonary disease, chronic obstructive 30.1 TNF MMP9 IL6 CXCL8
45 hydrocephalus 30.1 TNF GFAP GDNF CASP3 BDNF AQP4
46 duodenal ulcer 30.1 TNF IL6 CXCL8
47 esophagitis 30.1 TNF IL6 CXCL8
48 cerebrovascular disease 30.1 TNF MMP9 LEP IL6
49 osteoporosis 30.1 TNF MMP9 LEP IL6 CXCL8 BDNF
50 varicocele 30.0 NOS2 LEP IL6 CASP3

Graphical network of the top 20 diseases related to Spinal Cord Injury:

Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

MGI Mouse Phenotypes related to Spinal Cord Injury:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 AQP4 BDNF CASP3 GDNF GFAP GJA1
2 cellular MP:0005384 10.43 BDNF CASP3 CSPG4 GDNF GFAP GJA1
3 homeostasis/metabolism MP:0005376 10.43 AQP4 ARG1 BDNF CASP3 CSPG4 GFAP
4 growth/size/body region MP:0005378 10.4 AQP4 BDNF CASP3 CSPG4 GDNF GFAP
5 cardiovascular system MP:0005385 10.37 AQP4 CASP3 GDNF GFAP GJA1 GRIN1
6 mortality/aging MP:0010768 10.36 AQP4 ARG1 BDNF CASP3 GDNF GFAP
7 hematopoietic system MP:0005397 10.35 AQP4 ARG1 CASP3 CSPG4 GDNF GJA1
8 nervous system MP:0003631 10.33 AQP4 ARG1 BDNF CASP3 CSPG4 GDNF
9 digestive/alimentary MP:0005381 10.32 AQP4 BDNF CASP3 GDNF GFAP IL6
10 immune system MP:0005387 10.32 AQP4 ARG1 CASP3 CSPG4 GDNF GFAP
11 endocrine/exocrine gland MP:0005379 10.22 AQP4 BDNF CASP3 GDNF GJA1 IL6
12 integument MP:0010771 10.15 BDNF CASP3 GJA1 IL6 LEP MMP9
13 muscle MP:0005369 10.13 CASP3 GDNF GFAP GJA1 IL6 LEP
14 hearing/vestibular/ear MP:0005377 10.02 AQP4 BDNF CASP3 GJA1 GRIN1 NGFR
15 liver/biliary system MP:0005370 10.02 ARG1 CSPG4 IL6 LEP NGFR NOS2
16 no phenotypic analysis MP:0003012 9.97 AQP4 BDNF CASP3 CSPG4 GJA1 GRIN1
17 reproductive system MP:0005389 9.96 BDNF CASP3 GDNF GJA1 GRIN1 IL6
18 renal/urinary system MP:0005367 9.92 AQP4 CASP3 GDNF IL6 LEP MMP9
19 respiratory system MP:0005388 9.9 AQP4 BDNF CASP3 GJA1 GRIN1 IL6
20 vision/eye MP:0005391 9.4 AQP4 BDNF CASP3 GFAP GJA1 GRIN1
21 taste/olfaction MP:0005394 9.26 BDNF CASP3 GRIN1 NGFR

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 417)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
Oxybutynin Approved, Investigational Phase 4 5633-20-5 4634
Perphenazine Approved Phase 4 58-39-9 4748
Amitriptyline Approved Phase 4 50-48-6 2160
4-Aminopyridine Approved Phase 4 504-24-5 1727
Levetiracetam Approved Phase 4 102767-28-2 441341
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
Oxcarbazepine Approved Phase 4 28721-07-5 34312
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Norepinephrine Approved Phase 4 51-41-2 439260
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
Denosumab Approved Phase 4 615258-40-7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Morphine Approved, Investigational Phase 4 57-27-2 5288826
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
Baclofen Approved Phase 4 1134-47-0 2284
Cycloserine Approved Phase 4 68-41-7 401 6234
Glucagon Approved Phase 4 16941-32-5
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Fidaxomicin Approved Phase 4 873857-62-6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
41 Vasodilator Agents Phase 4
42 Phosphodiesterase 5 Inhibitors Phase 4
43 Phosphodiesterase Inhibitors Phase 4
44 Vardenafil Dihydrochloride Phase 4
45 Muscarinic Antagonists Phase 4
46 Cholinergic Antagonists Phase 4
47 Trospium chloride Phase 4 10405-02-4
48 Parasympatholytics Phase 4
49 Mandelic Acids Phase 4
50 Amitriptyline, perphenazine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 1326)
# Name Status NCT ID Phase Drugs
1 Assessment of Pregabalin Efficacy for the Treatment and Prevention of At-level Non-evoked and Evoked Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
2 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial Unknown status NCT03169582 Phase 4 Avanafil;Sildenafil
3 An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalk™ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury. Unknown status NCT01943669 Phase 4
4 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
5 Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 A Longitudinal Clinical Feasibility Study to Evaluate the Psychological and Functional Effects of Using the Tobii™ Eyegaze System by Inpatients With Tetraplegia Unknown status NCT01943656 Phase 4
7 Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury Unknown status NCT02298660 Phase 4 BOTOX
8 Analgesic and Hemodynamic Effects of Continuous Epidural Analgesia Compared to Paravertebral Block in Liver Resection Patients Unknown status NCT02909322 Phase 4
9 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
10 The Effect of Botulinum Toxin A in Post Spinal Cord Injury Neuropathic Pain Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
11 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
12 A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects Completed NCT02001558 Phase 4 Microcyn
13 Melatonin Replacement for Treatment of Sleep Disruption Completed NCT00507546 Phase 4 Ramelteon;Placebo
14 Management of Chronic Pain in Rehabilitation Project I - Management of Chronic Pain in Persons With Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
15 Double-blind, Cross-over, Placebo Controlled Pilot Study to Characterize the Profile of Those Patients With Spinal Cord Injury Diagnosed by Electrophysiological, Urodynamic and Clinical (ASIA Group) Assessment Who May Respond to Vardenafil Treatment. (LEMDE) Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
16 A Placebo-Controlled, Randomized, Two-Way Cross-Over, Double-Blind, Flexible Dose, Multicenter Study to Evaluate the Efficacy and Safety of Viagra in Male Patients With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
17 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury - a Prospective, Randomized, Controlled, Multicentre Trial of Transanal Irrigation Vs. Conservative Bowel Management Completed NCT00286520 Phase 4
18 Bowel Care and Cardiovascular Function After Spinal Cord Injury Completed NCT01567605 Phase 4 Lidocaine lubricant
19 Effects of Levetiracetam on Chronic Neuropathic Pain Following Spinal Cord Injury: a Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Completed NCT00252954 Phase 4 Levetiracetam
20 Omega-3 Supplementation to Increase HDL-c Levels in Those With Tetraplegia Completed NCT01896037 Phase 4
21 Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury Completed NCT00826228 Phase 4 teriparatide
22 Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
23 The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
24 A Randomized, Double-blind, Placebo-controlled Cross-over Trial Assessing the Effect of Tadalafil (Cialis) on the Cardiovascular System in Men With Complete Spinal Cord Injury (SCI) at or Above the Sixth Thoracic Level Completed NCT01067391 Phase 4 tadalafil;placebo
25 Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
26 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
27 Efficacy and Safety of Bowel Preparations for Colonoscopy in SCI Completed NCT00745095 Phase 4 Neostigmine
28 Core Temperature During Cold Exposure in Persons With Tetraplegia Completed NCT01822535 Phase 4 Midodrine hydrochloride
29 A Multi-center, Open-label, Dose-titration Pilot Study Evaluating the Efficacy and Safety of Oxybutynin Transdermal Systems in Patients With Neurogenic Bladder Resulting From Spinal Cord Injury Completed NCT00224029 Phase 4 Oxybutynin transdermal system
30 A Randomized, Double Blind, Double Dummy, Placebo Controlled Study to Evaluate the Efficacy and Safety of Solifenacin Succinate (5 and 10mg Once Daily) Against Placebo and Oxybutynin Hydrochloride (5 mg Three Times Daily) in the Treatment of Subjects With Neurogenic Detrusor Overactivity Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
31 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
32 A Prospective Randomized Controlled Trial of Standardized C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for the Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
33 Does Pretreated Magnesium Protect Against Reperfusion Injury in Liver Transplanted Patients? Completed NCT00994981 Phase 4 magnesium;normal saline
34 A Prospective, Randomized, Parallel-group, Multi-center Study to Compare the Occurrence of Urinary Tract Infections in Patients With Spinal Cord Injury Using Either Coated or Uncoated Intermittent Catheters. Completed NCT00318591 Phase 4
35 Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study. Completed NCT02146534 Phase 4 extended release fampridine;Placebo
36 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
37 Evaluation of the Safety of C-Spine Clearance by Emergency Department Triage Nurses (Phase IV) Completed NCT01353352 Phase 4
38 An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
39 A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Completed NCT02208050 Phase 4 Fampridine;Placebo
40 A Case Series of Patients With Spinal Cord Injury Treated With Standard Therapies and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
41 An Open-label, Single Centre Prospective Cohort Study to Determine the Effectiveness and Safety of Targin® for Pain Management and Opioid-induced Constipation in Patients With Spinal Cord Injury: Can we Improve Pain and Ameliorate Secondary Complications of Opioid Treatment? Recruiting NCT03179475 Phase 4 Oxycodone Naloxone Combination
42 Maximizing Spike - Timing Dependent Plasticity After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
43 The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain Recruiting NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
44 Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury Recruiting NCT04056988 Phase 4 Perflutren Lipid Microsphere
45 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
46 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
47 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
48 The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
49 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
50 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Recruiting NCT02379156 Phase 4 Midodrine Hydrochloride

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
RNL-Astrostem, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
HuCNS-SC, human central nervous system stem cells for neurological diseases
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
MultiStem, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
Schwann cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Oligodendrocyte progenitor-like cells PMIDs: 17253955 17996308
Human neural stem cells (HuCNS-SC) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 23098734 23186720 16629629
Schwann cells PMIDs: 23098734 23186720 16629629
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181
Bone marrow-derived mesenchymal stem cells

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

Spinal Cord, Bone, Brain, Testes, Bone Marrow, Heart, Cortex
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 33013)
# Title Authors PMID Year
Effectiveness of rehabilitation training combined acupuncture for the treatment of neurogenic bladder secondary to spinal cord injury. 61 42
31574865 2019
Successful treatment of a primary thoracic dumb-bell yolk sac tumor presenting with severe spinal cord compression: Case report. 42
31651872 2019
Risk factors of cage subsidence after removal of localized heterotopic ossification by anterior cervical discectomy and fusion: A retrospective multivariable analysis. 42
31626106 2019
Histological and functional outcomes in a rat model of hemisected spinal cord with sustained VEGF/NT-3 release from tissue-engineered grafts. 61
31899965 2020
Multimodal treatment for spinal cord injury: a sword of neuroregeneration upon neuromodulation. 61
31997803 2020
Expression of long non-coding RNAs in complete transection spinal cord injury: a transcriptomic analysis. 61
31997824 2020
Electrical stimulation and denervated muscles after spinal cord injury. 61
31997798 2020
Neuroprotective effect of deferoxamine on erastininduced ferroptosis in primary cortical neurons. 61
31997820 2020
Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial. 61
31997819 2020
The N-formyl peptide receptors: contemporary roles in neuronal function and dysfunction. 61
31960798 2020
Therapeutic effect of regulating autophagy in spinal cord injury: a network meta-analysis of direct and indirect comparisons. 61
31823893 2020
Comparative proteomes change and possible role in different pathways of microRNA-21a-5p in a mouse model of spinal cord injury. 61
31823891 2020
Global and site-specific analysis of bone in a rat model of spinal cord injury-induced osteoporosis. 61
31886322 2020
Three-dimensional bioprinting collagen/silk fibroin scaffold combined with neural stem cells promotes nerve regeneration after spinal cord injury. 61
31719263 2020
Changes in neurological and pathological outcomes in a modified rat spinal cord injury model with closed canal. 61
31638094 2020
Effects of neural stem cell transplantation on the motor function of rats with contusion spinal cord injuries: a meta-analysis. 61
31638100 2020
Unfolded protein response in myelin disorders. 61
31638085 2020
Long noncoding RNA PTENP1 affects the recovery of spinal cord injury by regulating the expression of miR-19b and miR-21. 61
31583718 2020
Protective effect of rhodioloside and bone marrow mesenchymal stem cells infected with HIF-1-expressing adenovirus on acute spinal cord injury. 61
31638093 2020
Effect of docosahexaenoic acid on the recovery of motor function in rats with spinal cord injury: a meta-analysis. 61
31571666 2020
Acute upregulation of bone morphogenetic protein-4 regulates endogenous cell response and promotes cell death in spinal cord injury. 61
31881217 2020
Oleanolic acid inhibits mouse spinal cord injury through suppressing inflammation and apoptosis via the blockage of p38 and JNK MAPKs. 61
31924596 2020
Human gingival derived neuronal cells in the optimized caffeic acid hydrogel for hemitransection spinal cord injury model. 61
31646674 2020
Characterization of transection spinal cord injuries by monitoring somatosensory evoked potentials and motor behavior. 61
31866455 2020
The Hemisection Approach in Large Animal Models of Spinal Cord Injury: Overview of Methods and Applications. 61
30380340 2020
Systemic inflammation in traumatic spinal cord injury. 61
31843491 2020
Research on the Effects of Levetiracetam in Spinal Cord Injury Model in Rats: An Experimental Study. 61
30204031 2020
Research on the Effects of Levetirasetam in Spinal Cord Injury Model. 61
30430869 2020
MicroRNA-26b inhibits oligodendrocyte precursor cell differentiation by targeting adrenomedullin in spinal cord injury. 61
31489964 2020
Pharmacokinetics and anti-inflammatory effect of naproxen in rats with acute and subacute spinal cord injury. 61
31641817 2020
Management of the Patient with Chronic Spinal Cord Injury. 61
32035568 2020
Neurological recovery and antioxidant effects of resveratrol in rats with spinal cord injury: a meta-analysis. 61
31571660 2020
Neck Injuries. 61
32014132 2020
Hepatic dysfunction after spinal cord injury: A vicious cycle of central and peripheral pathology? 61
31863731 2020
Taking central nervous system regenerative therapies to the clinic: curing rodents versus nonhuman primates versus humans. 61
31571651 2020
Inhibiting store-operated calcium entry attenuates white matter secondary degeneration following SCI. 61
31846736 2020
Exercise in multiple sclerosis and its models: Focus on the central nervous system outcomes. 61
31486115 2020
Guidance for behavioural interventions aiming to support family support providers of people with spinal cord injury: A scoping review. 61
31958615 2020
Gender, class, employment status and social mobility following spinal cord injury in Denmark, the Netherlands, Norway and Switzerland. 61
31575981 2020
Grafting Embryonic Raphe Neurons Reestablishes Serotonergic Regulation of Sympathetic Activity to Improve Cardiovascular Function after Spinal Cord Injury. 61
31896670 2020
Spinal instability causing upper motor neuron to lower motor neuron symptom transition in chronic spinal cord injury. 61
32022427 2020
Single-session cortical electrical stimulation enhances the efficacy of rehabilitative motor training after spinal cord injury in rats. 61
31786212 2020
Melatonin exerts neuroprotective effects by attenuating astro- and microgliosis and suppressing inflammatory response following spinal cord injury. 61
31902595 2020
Development of an unsupervised machine learning algorithm for the prognostication of walking ability in spinal cord injury patients. 61
31525468 2020
Family-centered empowerment process in individuals with spinal cord injury living in Iran: a grounded theory study. 61
31477808 2020
Multicenter study of 37 pediatric patients with SCIWORA or other spinal cord injury without associated bone lesion. 61
31786134 2020
Evaluation for Late Nerve Transfer Surgery in Spinal Cord Injury: Predicting the Degree of Lower Motor Neuron Injury. 61
31866150 2020
Peak power output in handcycling of individuals with a chronic spinal cord injury: predictive modeling, validation and reference values. 61
30507314 2020
Publicly funded home care service use in the first 2 years after spinal cord injury in Ontario, Canada. 61
32009576 2020
Arm crank ergometer "spin" training improves seated balance and aerobic capacity in people with spinal cord injury. 61
31621945 2020

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
5 12.81 NOS2 MMP9 IL6 CXCL8 CASP3
Show member pathways
Show member pathways
12.29 TNF NOS2 IL6 CXCL8
9 12.28 TNF IL6 CXCL8 CASP3
10 12.24 NGFR MMP9 IL6 CXCL8
Show member pathways
12 12.22 TNF NOS2 IL6 CASP3
Show member pathways
12.21 TNF NOS2 IL6 CXCL8
Show member pathways
12.16 TNF NOS2 IL6 CXCL8
15 12.13 TNF NOS2 MMP9 IL6 CASP3
17 11.96 TNF MMP9 IL6 CASP3
18 11.89 TNF IL6 CXCL8 CASP3
19 11.89 TNF NOS2 MMP9 IL6 CXCL8
21 11.76 NOS2 IL6 CXCL8
Show member pathways
24 11.74 TNF NOS2 IL6 CXCL8 CASP3 ARG1
25 11.67 NOS2 MMP9 CASP3
Show member pathways
28 11.65 MMP9 IL6 CXCL8 CASP3
29 11.65 TNF NOS2 IL6 CXCL8 CASP3
30 11.62 TNF MMP9 IL6 CXCL8
31 11.55 TNF IL6 CXCL8 CASP3
32 11.53 TNF IL6 CXCL8
33 11.52 TNF IL6 CXCL8
34 11.52 NOS2 IL6 CXCL8 ARG1
Show member pathways
36 11.5 TNF NOS2 KLK8
37 11.5 TNF MMP9 IL6
38 11.48 TNF NOS2 MMP9 IL6 BDNF ARG1
39 11.47 RTN4R NGFR ARG1
40 11.47 NOS2 IL6 CXCL8 CASP3
41 11.3 TNF NGFR CASP3
42 11.24 MMP9 IL6 GJA1 CXCL8
43 11.1 TNF LEP IL6
44 11.02 TNF IL6 CXCL8

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNF MMP9 LEP KLK8 IL6 GDNF
2 membrane raft GO:0045121 9.56 TNF RTN4R GJA1 CASP3
3 extracellular region GO:0005576 9.4 TNF NGFR MMP9 LEP KLK8 IL6
4 astrocyte end-foot GO:0097450 8.96 GFAP AQP4

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 NGFR MMP9 LEP IL6 GDNF CASP3
2 response to lipopolysaccharide GO:0032496 9.85 NOS2 GJA1 CASP3 ARG1
3 memory GO:0007613 9.8 KLK8 GRIN1 BDNF
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.78 TNF LEP IL6
5 neuron projection morphogenesis GO:0048812 9.77 KLK8 GJA1 BDNF
6 regulation of insulin secretion GO:0050796 9.76 TNF NOS2 LEP
7 response to glucocorticoid GO:0051384 9.75 TNF IL6 CASP3
8 positive regulation of apoptotic process GO:0043065 9.73 TNF NGFR MMP9 IL6 GRIN1 CASP3
9 cellular response to amyloid-beta GO:1904646 9.7 NGFR GRIN1 GJA1
10 positive regulation of neuroinflammatory response GO:0150078 9.63 TNF IL6
11 negative regulation of activated T cell proliferation GO:0046007 9.63 CASP3 ARG1
12 negative regulation of axon regeneration GO:0048681 9.62 RTN4R KLK8
13 response to wounding GO:0009611 9.62 KLK8 GFAP CASP3 ARG1
14 regulation of neuroinflammatory response GO:0150077 9.61 MMP9 IL6
15 positive regulation of JAK-STAT cascade GO:0046427 9.61 TNF LEP IL6
16 response to vitamin E GO:0033197 9.6 LEP ARG1
17 neurotrophin TRK receptor signaling pathway GO:0048011 9.58 NGFR CASP3 BDNF
18 positive regulation of receptor binding GO:1900122 9.57 MMP9 BDNF
19 arginine catabolic process GO:0006527 9.56 NOS2 ARG1
20 cellular response to lipopolysaccharide GO:0071222 9.55 TNF NOS2 IL6 CXCL8 ARG1
21 regulation of cytokine production involved in inflammatory response GO:1900015 9.54 NOS2 LEP
22 positive regulation of glial cell proliferation GO:0060252 9.54 TNF IL6 GFAP
23 interleukin-8 secretion GO:0072606 9.51 NOS2 LEP
24 interleukin-6 secretion GO:0072604 9.49 NOS2 LEP
25 prostaglandin secretion GO:0032310 9.48 NOS2 LEP
26 cytokine-mediated signaling pathway GO:0019221 9.43 TNF NOS2 MMP9 IL6 CXCL8 CASP3
27 negative regulation of lipid storage GO:0010888 8.8 TNF LEP IL6

Sources for Spinal Cord Injury

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....